Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + pemigatinib
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of sintilimab, a recombinant humanized IgG4 monoclonal antibody, and pemigatinib, an orally bioavailable small-molecule inhibitor of fibroblast growth factor receptors (FGFR). Sintilimab functions as a checkpoint inhibitor by binding to the programmed cell death protein 1 (PD-1) receptor on T cells, blocking its interaction with ligands PD-L1 and PD-L2 to restore anti-tumor immune responses. Pemigatinib selectively inhibits FGFR1, 2, and 3, which are often dysregulated in various cancers. In the context of intrahepatic cholangiocarcinoma (iCCA), pemigatinib specifically targets FGFR2 fusions or rearrangements that drive tumor growth. The combination is being evaluated by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as a first-line treatment for advanced unresectable or metastatic iCCA, aiming to leverage the synergistic effects of targeted kinase inhibition and immune checkpoint blockade.
- Other names
- sintilimabpemigatinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sintilimab + pemigatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + pemigatinib.